{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:17:25Z","timestamp":1792513045733,"version":"4.5.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Relmacabtagene autoleucel (relma-cel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, is approved in China for relapsed\/refractory (R\/R) large B-cell lymphoma and follicular lymphoma. This phase 2, open-label, single-arm, multicenter study evaluated its efficacy and safety in Chinese patients with heavily pretreated R\/R mantle cell lymphoma (MCL). A total of 70 patients with R\/R MCL who had received 1 to 9 previous therapies (including anthracycline or bendamustine chemotherapy, anti-CD20 antibodies, and Bruton tyrosine kinase [BTK] inhibitors) were enrolled. Of these, 59 received a single infusion of 100 \u00d7 106 CAR-positive T cells following leukapheresis. The primary end point was the objective response rate (ORR) at 3 months after infusion, assessed using the Lugano 2014 criteria. Secondary end points included the duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. At 3 months, the ORR was 71.19% (95% confidence interval [CI], 57.92-82.24) with a complete response rate of 59.32% (95% CI, 45.75-71.93). After a median follow-up of 13.3 months (95% CI, 9.04-18.69), the median DOR was 18.1 months, PFS was 15.5 months, and OS was 19.5 months. Grade 3 or higher treatment-emergent adverse events were common, including neutropenia (76.3%), leukopenia (69.5%), and lymphopenia (47.5%). Severe cytokine release syndrome and neurotoxicity occurred in 6.8% of patients each, and all cases resolved fully. No fatal events were reported. These findings demonstrate that relma-cel offers high response rates, durable remissions, and manageable safety in Chinese patients with R\/R MCL. This trial was registered at www.clinicaltrials.gov as #NCT04718883.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015763","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T20:56:57Z","timestamp":1755205017000},"page":"1134-1144","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed\/refractory mantle cell lymphoma in Chinese adults"],"prefix":"10.1182","volume":"10","author":[{"given":"Yan","family":"Xie","sequence":"first","affiliation":[{"name":"1Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5467-1377","authenticated-orcid":false,"given":"Ke-Shu","family":"Zhou","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Fang","family":"Li","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Bin","family":"Liang","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7941-2443","authenticated-orcid":false,"given":"Heng","family":"Mei","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8135-4913","authenticated-orcid":false,"given":"De-hui","family":"Zou","sequence":"additional","affiliation":[{"name":"6Department of Lymphoma, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Yu","family":"Li","sequence":"additional","affiliation":[{"name":"7Department of Lymphoma, Guangdong Academy of Medical Science, Guangdong Provincial People's Hospital, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"8Department of Hematology, The First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Ming","family":"Jin","sequence":"additional","affiliation":[{"name":"9Department of Hematology, First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Mei","family":"Jing","sequence":"additional","affiliation":[{"name":"10Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Yang","sequence":"additional","affiliation":[{"name":"11Department of Lymphoma, Zhejiang Cancer Hospital, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Chen","sequence":"additional","affiliation":[{"name":"12Division of Hematology, Huashan Hospital of Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Qiang","family":"Huang","sequence":"additional","affiliation":[{"name":"13Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Cheng","family":"He","sequence":"additional","affiliation":[{"name":"14Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ning","family":"Cao","sequence":"additional","affiliation":[{"name":"15Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Xia","sequence":"additional","affiliation":[{"name":"16Department of Clinical Development, JW Therapeutics (Shanghai) Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-En","family":"Gu","sequence":"additional","affiliation":[{"name":"16Department of Clinical Development, JW Therapeutics (Shanghai) Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Bei","family":"Zang","sequence":"additional","affiliation":[{"name":"16Department of Clinical Development, JW Therapeutics (Shanghai) Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Song","family":"Zhou","sequence":"additional","affiliation":[{"name":"16Department of Clinical Development, JW Therapeutics (Shanghai) Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Zhao","family":"Tian","sequence":"additional","affiliation":[{"name":"16Department of Clinical Development, JW Therapeutics (Shanghai) Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3479-2547","authenticated-orcid":false,"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qin","family":"Song","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"6","key":"2026022411384117100_bib1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management","volume":"94","author":"Jain","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"2026022411384117100_bib2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.critrevonc.2011.05.001","article-title":"Mantle cell lymphoma","volume":"82","author":"Cortelazzo","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"2026022411384117100_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"10121","key":"2026022411384117100_bib4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"The Lancet"},{"issue":"26","key":"2026022411384117100_bib5","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"2026022411384117100_bib6","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/hon.2380","article-title":"Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma\u2014a \u201creal world\u201d study","volume":"35","author":"Epperla","year":"2017","journal-title":"Hematol Oncol"},{"issue":"4","key":"2026022411384117100_bib7","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"2026022411384117100_bib8","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2026022411384117100_bib9","first-page":"3745","article-title":"Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry","volume":"109","author":"Herbaux","year":"2024","journal-title":"Haematologica"},{"issue":"6","key":"2026022411384117100_bib10","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1002\/hem3.87","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis","volume":"8","author":"O'Reilly","year":"2024","journal-title":"Hemasphere"},{"issue":"2","key":"2026022411384117100_bib11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/bjh.19961","article-title":"Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study","volume":"206","author":"Stella","year":"2025","journal-title":"Br J Haematol"},{"issue":"14","key":"2026022411384117100_bib12","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026022411384117100_bib13","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a Phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"14","key":"2026022411384117100_bib14","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"27","key":"2026022411384117100_bib15","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026022411384117100_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"21","key":"2026022411384117100_bib17","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","article-title":"Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry","volume":"7","author":"Lemoine","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026022411384117100_bib18","first-page":"1","article-title":"Relma-cel elicited durable remission in a r\/r MCL patient with high-risk factors: a case report","volume":"10","author":"Xie","year":"2024","journal-title":"Oncol Cancer Case Rep"},{"issue":"1","key":"2026022411384117100_bib19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/jamaoncol.2023.4504","article-title":"Implications of high tumor burden on chimeric antigen receptor T-cell immunotherapy: a review","volume":"10","author":"Ventin","year":"2024","journal-title":"JAMA Oncol"},{"issue":"23","key":"2026022411384117100_bib20","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1158\/1078-0432.CCR-19-0101","article-title":"Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin's lymphoma","volume":"25","author":"Yan","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2026022411384117100_bib21","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1002\/cam4.4071","article-title":"Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer","volume":"10","author":"Cao","year":"2021","journal-title":"Cancer Med"},{"issue":"4","key":"2026022411384117100_bib22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jcyt.2022.11.003","article-title":"Mesenchymal stem\/stromal cells from a transplanted, asymptomatic patient with Fanconi anemia exhibit an aging-like phenotype and dysregulated expression of genes implicated in hematopoiesis and myelodysplasia","volume":"25","author":"Haga","year":"2023","journal-title":"Cytotherapy"},{"issue":"8","key":"2026022411384117100_bib23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/s41409-023-01989-3","article-title":"Prognostic factors and clinical outcomes in patients with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation","volume":"58","author":"Gao","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"2026022411384117100_bib24","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s11912-022-01286-0","article-title":"BTK inhibitors and CAR T-cell therapy in treating mantle cell lymphoma\u2014finding a dancing partner","volume":"24","author":"Munoz","year":"2022","journal-title":"Curr Oncol Rep"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1134\/2503763\/blooda_adv-2024-015763-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1134\/2503763\/blooda_adv-2024-015763-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:38:48Z","timestamp":1771951128000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/4\/1134\/546727\/Phase-2-study-of-relmacabtagene-autoleucel-CD19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015763","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,24]]},"published":{"date-parts":[[2026,2,13]]}}}